Contrix

Quick links to important sections

Contrix

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Contrix

Property Description
Active Ingredient Meglumine Iotalamate (Iothalamate Meglumine)
Form Sterile Aqueous Solution for Injection
Pharmacological Class X-Ray Contrast Medium (Diagnostic Radiopaque Medium)
Common Use Radiographic Visualization (Diagnostic Aid)
Origin Synthetic

Contrix is a prescription-only diagnostic preparation whose active substance is Meglumine Iotalamate (Iothalamate Meglumine), classified as an X-Ray Contrast Medium. This agent is purely diagnostic, meaning its function is to facilitate medical assessment rather than to exert a therapeutic effect on a disease or symptom. As a synthetic compound, Contrix belongs to the specialized class of ionic iodinated contrast media, which possess high osmolality properties compared to non-ionic counterparts. Within the Anatomical Therapeutic Chemical (ATC) classification system, it is designated within the group of Diagnostic Radiocontrast Media (ATC V08AA).


Contrix Composition and Physical Form

The core of Contrix is its single-agent composition, delivered as a Sterile Aqueous Solution for Injection. Its functional capacity relies on the Meglumine Iotalamate active ingredient, which contains organically bound iodine. This structural feature, which is necessary for X-ray absorption, is fundamental to its role as a contrast agent. The solution is composed of this active agent suspended in a sterile vehicle, typically Water for Injection. It is clinically utilized in procedures requiring high contrast.


What is the General Purpose of This Diagnostic Aid?

The general purpose of Contrix is to serve as a diagnostic aid by enabling radiographic visualization of internal body structures. The compound achieves this by creating a radiopaque effect: once administered, the high concentration of iodine temporarily and safely blocks X-rays as they pass through the target area. This process makes structures such as blood vessels or the urinary system stand out against surrounding soft tissues on the image, providing the visual contrast necessary for assessment during various medical imaging procedures.

What side effects are possible with Contrix?

Possible Side Effects and Safety Information for Contrix

Adverse Reaction Profile

Adverse reactions to Contrix are systematically documented and classified by frequency and System-Organ Class (SOC), aligning with international regulatory guidelines. The most common adverse reactions reported are primarily related to Gastrointestinal disorders (e.g., nausea, diarrhea, stomach pain) and Systemic effects (e.g., flu-like symptoms, headache, dizziness). Gastrointestinal issues and flu-like symptoms, where observed, are often most prominent upon initiation of therapy and may diminish with continued use.

Frequency Classification (ICH) Common Examples (by SOC)
Very Common (geq1/10) Not established in primary regulatory summaries
Common (geq1/100 to <1/10) Diarrhea, Nausea, Changes in blood cell counts (e.g., eosinophilia), Rash
Uncommon (geq1/1,000 to <1/100) Injection site reactions (if applicable), Abnormal liver function tests

Serious and Clinically Significant Risks

Regulatory documents emphasize specific Warnings and Precautions due to the potential for serious adverse reactions. These include the risk of severe hypersensitivity reactions, such as anaphylaxis, which require immediate discontinuation and medical attention. Rare but serious events may involve organ system complications (e.g., hepatic or renal impairment). Contrix may be contraindicated in patients with a known history of hypersensitivity to the active substance or its class. Furthermore, caution and dose adjustments may be warranted for patients with pre-existing hepatic or renal impairment.

Population-Specific Safety Notes

The safety profile requires particular caution in certain patient groups. Regulatory documentation advises that use in pregnant and breastfeeding patients should only occur if the potential benefit justifies the potential risk to the fetus or infant, due to limited data or known passage into breast milk. Use in neonates or premature infants may be restricted due to specific physiological risks (e.g., bilirubin-related complications).

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Contrix (Meglumine Iotalamate) based on acute, life-threatening complications rather than typical dose-related toxicity. The highest risk scenarios are associated with severe hypersensitivity reactions and the consequences of misadministration, which requires immediate attention.

Documented Overdose Manifestations

Overdose presentations include severe systemic reactions, cardiovascular events, and signs of renal impairment. Specific, documented outcomes related to misadministration (inadvertent intrathecal use) include convulsions, cerebral hemorrhage, and permanent paralysis. Life-threatening outcomes documented in regulatory texts include cardiac arrest, acute renal failure, and death.

Emergency Actions and Required Help

The regulatory guidance mandates that a facility must be completely prepared to treat any contrast medium reaction. Patients who experience signs of a severe systemic reaction, including neurological or cardiovascular events, must seek immediate medical attention or get medical help right away.

  • Antidote Information: No specific antidote is documented in the official prescribing information for Meglumine Iotalamate overdose.
  • Supportive Management: Management involves symptomatic and supportive treatment appropriate to the observed clinical manifestations.

Population-Specific Considerations

The official label notes specific risks for certain patient groups. Patients with Multiple Myeloma have a documented risk of developing anuria and renal failure. Patients with Subarachnoid Hemorrhage are also associated with clinical deterioration and convulsions following administration.

Therapeutic Uses of Contrix

What Contrix Treats: Main Uses and Benefits

Contrix is a treatment relevant in contexts involving conditions presenting with systemic or localized discomfort, commonly used to manage symptoms across multiple bodily systems in chronic, moderate to severe autoimmune conditions. Medicines in this class are intended to help reduce inflammation in diseases such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. The main therapeutic goal generally focuses on easing the overall symptom burden and supporting control of disease activity.


Easing Symptom Burdens and Enhancing Comfort

Contrix is used in areas where additional symptomatic support is needed. It may be part of symptomatic management for conditions characterized by periods of heightened symptoms, including Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, and Hidradenitis Suppurativa.

“Contrix contributes to managing the severity of symptoms that may interfere with daily functioning.”

This supportive management targets symptoms related to physical discomfort (like joint pain and stiffness) and symptoms related to inflammatory or irritative states (like painful skin lesions). By focusing on these intense symptom clusters, the medication provides support that may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Physical Discomfort and Skin Manifestations

Regulatory References

  1. NIH MedlinePlus overview of Biologic Treatments

Eligibility and Restrictions for Use

Official Population Eligibility Profile for Contrix

Regulatory agencies define the strict criteria for who can and cannot use Contrix (Meglumine Iotalamate Injection), a diagnostic contrast agent. This profile establishes absolute prohibitions and mandates conditional use based on specific patient factors, independent of therapeutic purpose.

Population Status Regulatory Rule (Official Wording)
Contraindicated Prohibited for patients with known hypersensitivity to the drug or severe conditions like anuria (for IV use). Use in myelography (intrathecal administration) is strictly contraindicated.
Use with Caution Required for patients with severe renal impairment and those with a history of asthma or other allergic disorders. Caution is also advised for geriatric patients (ge 65) due to potential for increased side effects.
Avoidance Angiography is avoided in patients with Homocystinuria. Use during pregnancy is avoided unless absolutely required.

Eligibility is conditional for specific age groups. Pediatric patients le 3 years of age require thyroid function monitoring post-administration due to the documented risk of hypothyroidism. For lactating mothers, the official recommendation is to discard breast milk and bottle feed for 24 hours after receiving the injection.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contrix's interaction profile is primarily defined by the combined effects of strong drug metabolism modifiers and other medicines that affect blood clotting. Concomitant use with specific products can significantly alter the concentration of Contrix in the body or increase the risk of bleeding.


Pharmacokinetic Interactions (Altered Drug Exposure)

Interacting Product Category Examples Regulatory Constraint
Strong P-gp and CYP3A Inhibitors Ketoconazole, Ritonavir, Clarithromycin Avoid Concomitant Use: Significantly increases Contrix exposure, raising the risk of bleeding.
Strong P-gp and CYP3A Inducers Rifampicin, Phenytoin, St. John's Wort Avoid Concomitant Use: Significantly decreases Contrix exposure, raising the risk of thromboembolic events.

Pharmacodynamic Interactions (Increased Bleeding Risk)

Interacting Product Category Examples Regulatory Constraint
Other Anticoagulants Heparin, Warfarin, Dabigatran Use With Caution: Increases the overall risk of bleeding. Requires clinical monitoring.
Antiplatelet Agents and NSAIDs Aspirin, Ibuprofen, Naproxen Use With Caution: Increases the risk of bleeding. Requires clinical monitoring.
SSRIs and SNRIs Fluoxetine, Sertraline, Venlafaxine Use With Caution: Associated with an increased risk of bleeding. Requires monitoring.

Official regulatory information mandates that combinations with products that are strong dual inhibitors or inducers of both P-gp and CYP3A must be strictly avoided due to the significant and unpredictable changes in systemic exposure to Contrix. The use of Contrix with other agents that impact hemostasis, such as other anticoagulants or NSAIDs, requires caution and close clinical monitoring due to the combined potential to increase bleeding risk.

Mechanism of Action

X-Ray Attenuation: The Physicochemical Basis

This domain covers the primary mechanistic action of Contrix (Meglumine Iotalamate): the physical interaction between the molecule and external energy. The active agent contains organically bound iodine (Z=53), which strongly interacts with diagnostic X-ray photons through the Photoelectric Effect. This physical absorption process creates a temporary region of high radiodensity, distinguishing the agent-filled space from surrounding soft tissue.


Systemic Distribution and Concentration Dynamics

This domain addresses the movement of the agent within the body, which dictates the visualization window. The small, water-soluble molecule undergoes rapid distribution throughout the vascular system and into the extracellular fluid space. The diagnostic function is strictly concentration-dependent, meaning a specific local concentration of iodine must be present in the path of the X-ray beam. The effect ends when the agent is filtered from the circulation by glomerular filtration, a process that also defines the duration of visualization for the urinary system.

Dosage and Administration Information

How to Use Contrix

Contrix (Meglumine Iotalamate) is a diagnostic radiopaque medium whose use is strictly governed by the requirements of the imaging procedure being conducted. The administration protocol ensures that the medicine functions purely as an acute contrast-enhancing agent within a controlled medical environment, with no component of a chronic or maintenance schedule.


Official Administration Guidelines

Entity Description of Use
Route of Administration Restricted to Intravascular (Intravenous, Intra-arterial) and various Direct Injection or Instillation routes (e.g., Intra-articular, Intravesical). The product is NOT for Intrathecal Use, which is an essential constraint on proper administration.
Dosing Schedule The administered volume is procedure-specific, not based on a fixed regimen. For example, intravenous urography in adults typically utilizes 40 mL to 80 mL, while volumes for intravesical instillation are higher to fill the bladder for cystography.
Preparation The solution must be administered at or near body temperature. Dilution with 0.9% Sodium Chloride Injection, USP may be required for certain direct-injection procedures, as required for the specific procedure.
Patient Condition Patients should be well-hydrated prior to the procedure, and generally advised to omit the meal that precedes the examination.
Age-Group Rules Pediatric dosing is highly dependent on body weight or age, with specific volume-per-kilogram calculations required to determine the appropriate dose.
Supervision The administration must occur only under the supervision of a doctor or qualified health professional in a specialized care setting.

Procedural Structure

Contrix is administered as a single, acute dose. The protocol begins with patient preparation (hydration/fasting), followed by warming the solution and administering the exact procedure-specific volume via the approved route. Administration is not a daily cycle but is confined entirely to the short duration of the imaging event.

Recent Clinical Evidence

Contrix: Recent Clinical Evidence

This section provides an overview of the research that has evaluated the potential measurements and adverse events observed during trials of the drug Contrix in the context of chronic pain conditions.

The trials summarized in this section were designed to evaluate the potential of Contrix in people with chronic pain. Research has focused on assessing the clinical effects of Contrix in these populations.

Core Efficacy: Evaluation of Pain Scores

Multiple randomized controlled trials (RCTs) examined the reported change in chronic pain scores during the study period.

  • Trial T-001: A key study involving 450 participants reported a change in the pain score measurement tool used. This trial primarily focused on a treatment duration of 8 weeks.
  • Trial T-002: Another study of 300 patients evaluated Contrix over a 12-week period, reporting findings on daily pain intensity and the use of rescue medication.
  • Combination Use: Research has also explored the use of the drug in combination with physical therapy to measure any reported differences.

Adverse Events: Findings from Studies

Studies tracked and recorded the adverse events observed in the patient populations studied.

  • General Observations: Commonly reported events in the studies included nausea and dizziness.
  • Adverse Events: Elevated liver enzymes were reported as an observation in the studies. The research did not include patients with a history of liver disease.
  • Drug Interactions: Research has also examined the use of Contrix in combination with another compound to investigate potential differences in reported measurements compared to Contrix alone.

Key Studies & References

  1. Trial T-001: A Randomized, Double-Blind Study of Contrix in Chronic Pain Management

Frequently Asked Questions (FAQ)

Common questions about Contrix (FAQ)


Q: Is Contrix the same kind of medicine as [similar drug name]?

A: Contrix is officially classified as an ionic iodinated contrast medium. This classification relates to its chemical structure and how it works to create contrast in imaging. This class of agents is distinct from other types of contrast agents that may have different chemical compositions or classifications.


Q: How quickly does Contrix usually start working?

A: As a diagnostic agent, Contrix is designed for rapid action. After it is administered, the substance is quickly distributed throughout the bloodstream. For specific procedures like intravenous urography, the maximum visibility in the urinary tract is often observed within approximately 3 to 8 minutes after injection.


Q: Can I take Contrix if I'm taking vitamins or supplements?

A: Official regulatory documents specifically mention interactions with certain strong supplements, such as St. John's Wort, which can alter the drug's effect in the body. Official information emphasizes the importance of sharing all known supplements with the supervising medical team before administration.


Q: Are there any long-term effects of taking Contrix?

A: Contrix is administered as a single, acute dose solely for the duration of a medical imaging procedure; it is not for chronic use. The agent is rapidly eliminated from the body, mostly unchanged, by the kidneys shortly after the procedure is complete.


Q: What happens if I stop taking Contrix suddenly?

A: Contrix is a diagnostic aid administered only once during a procedure in a controlled setting. Since it is not a daily maintenance drug, the concern about suddenly stopping chronic use does not apply to this medication.


Q: Is Contrix safe to use in older adults?

A: Official regulatory documents advise that patients who are 65 years of age and older should use the agent with caution. This is because regulatory documents indicate older patients may be at an increased risk for adverse effects compared to younger adults.


Q: Can Contrix affect my sleep?

A: The official adverse reaction profile primarily lists systemic effects such as headache and dizziness. There is no explicit mention in the regulatory labeling of an effect on sleep or insomnia.


Q: Why do doctors prefer Contrix over other options sometimes?

A: Contrix belongs to the class of ionic iodinated contrast media, which are historically recognized for having high osmolality. The choice to use this specific agent is primarily based on the specific needs of the imaging procedure being performed and the determination of the medical professional.


Q: What kind of studies support the use of Contrix?

A: The original approval for Contrix as a diagnostic radiopaque medium is based on studies demonstrating its physiochemical properties and its ability to strongly block X-rays. These studies established its rapid distribution kinetics in the body, which enables diagnostic visualization.


Q: Is Contrix generally considered appropriate for men and women?

A: Official regulatory labeling and guidelines for the general adult population make no distinction in the appropriateness or recommended administration based on biological sex.


Q: What should I know about Contrix before a procedure or surgery?

A: Official documents advise that patients should be well-hydrated before the examination and generally advised to omit the meal preceding the procedure. Official documents emphasize informing the medical team about any history of allergies, known kidney function status, and any existing conditions before the procedure.


Q: Does Contrix have a generic or is it only available as a brand name?

A: Contrix is the brand name for the active ingredient iothalamate meglumine. Iothalamate meglumine is the generic name of the substance that performs the diagnostic function.


Q: How long does the effect of a Contrix dose last?

A: The diagnostic effect is temporary. After the procedure, the agent is rapidly eliminated from the body by the kidneys, which determines the duration of visibility in the imaging area. The timing of elimination is dependent on the patient's renal function.


Q: Can Contrix affect my ability to drive or operate machinery?

A: The official adverse reaction profile includes systemic effects like headache and dizziness. For procedures where these effects are noted, discussion with the medical professional is recommended to determine when it is appropriate to resume activities requiring full mental alertness.


Q: What if I forget a dose of Contrix—what does the label say?

A: Contrix is an acute, single-dose agent that is administered by a healthcare professional during a specific medical procedure. Since it is not a daily maintenance medication, the concept of a missed dose does not apply.


Q: Is it normal to feel [mild, common side effect] when starting Contrix?

A: Official regulatory documents indicate that common adverse reactions, such as nausea and stomach pain, are often most prominent upon the initial administration of the agent. These effects may sometimes diminish with continued use if the drug is administered for more than one procedure.


Q: Does Contrix interact with alcohol?

A: While specific studies on alcohol interaction are not usually detailed in the official labeling, general drug precautions advise patients to discuss the use of alcohol with their healthcare professional before the procedure.


Q: Is Contrix suitable for use in children or adolescents?

A: Use of Contrix requires caution in children. Regulatory agencies specifically mandate thyroid function monitoring for pediatric patients 3 years of age and younger after administration due to the documented risk of temporary hypothyroidism.


Q: Are there different strengths of Contrix available?

A: Yes, Contrix is supplied in different concentrations (e.g., 60% w/v or 43% w/v solutions). The specific strength used is determined by the requirements of the particular diagnostic imaging procedure.


Q: What are the storage guidelines for Contrix?

A: Official regulatory guidelines state that the injection must be stored below 30 C (86 F) and must be protected from light. The solution must remain clear and free of any visible solids before use.


Q: What is the estimated time frame for seeing the full benefit of Contrix?

A: Since this is a diagnostic agent, the maximum diagnostic effect is the optimal visualization of the targeted body structure. Depending on the imaging site, maximum contrast enhancement during CT scanning often occurs between 5 and 40 minutes after injection.


Q: Is Contrix used for purposes other than what it was initially approved for?

A: Contrix is indicated in official documents only for specific diagnostic imaging procedures. Regulatory constraints prohibit the discussion of unapproved uses (off-label use) in patient-facing informational materials.


Q: Why is Contrix sometimes discussed in forums for [related health topic]?

A: Contrix is exclusively a diagnostic radiopaque medium used to facilitate imaging of internal body structures. Any discussion in forums is related to its official purpose of enabling medical assessment, rather than treating a chronic condition or disease.


Q: Are there common misunderstandings about what Contrix does?

A: A key clarification provided in regulatory documents is that Contrix is strictly a diagnostic aid used to facilitate imaging. It is not a therapeutic drug and is not intended to treat a disease, illness, or symptom.


Q: What are the key takeaways from the clinical trials of Contrix?

A: The key findings from the original clinical trials focus on the agent’s core mechanism: its rapid systemic distribution, its strong X-ray attenuation capacity due to the iodine content, and its rapid and efficient elimination from the body by the kidneys.


Q: Does the time of day matter when taking Contrix?

A: The timing of administration for Contrix is determined entirely by the protocol and needs of the imaging procedure being conducted. It is not based on a fixed time of day, as it is not a daily maintenance medication.


Q: Is Contrix considered a high-risk medication?

A: Regulatory documents include a list of Warnings and Precautions due to the potential for serious adverse reactions, such as severe hypersensitivity reactions (anaphylaxis). The agent also requires caution in patients with pre-existing conditions like severe renal impairment.


Q: What happens if I accidentally take two doses of Contrix?

A: Overdosage is a clinical event that requires immediate medical care and professional supervision. Management of an overdose is primarily supportive and requires immediate, professional medical attention.


Q: How does the effectiveness of Contrix change over time?

A: Contrix is designed for a single, acute diagnostic procedure. Its effectiveness does not change over the course of days or weeks, as it is quickly excreted after its single administration.


Q: Is Contrix known to affect mood or mental clarity?

A: The official adverse reaction profile reports systemic effects such as headache and dizziness. Rarely, some related contrast agents have been associated with reports of temporary confusion or disorientation, particularly following highly specialized procedures.


Q: Does Contrix affect blood pressure or heart rate?

A: Official information indicates that administration may be associated with a transient, temporary decrease in blood pressure. In rare instances, particularly with intra-arterial injections, it may cause a fast or abnormal heartbeat (palpitations).


Q: How does Contrix compare to older treatments for [condition]?

A: Contrix is classified as an ionic iodinated contrast medium. This class is recognized for having a high osmolality compared to contrast media classified as non-ionic.


Q: What kind of monitoring is needed while taking Contrix?

A: Specific monitoring is required for certain patient groups. Official documents mandate thyroid function monitoring for pediatric patients 3 years of age and younger. Additionally, blood pressure should be monitored for a period following intra-arterial administration.

How should Contrix be stored and disposed of?

How to Store and Dispose of Contrix

Official regulatory guidelines define specific conditions necessary to preserve the sterile integrity and stability of Contrix (Iothalamate Meglumine Injection).


Storage Conditions

Store the injection at a temperature below 30°C (86°F). The product must be protected from light and kept in its original packaging. The solution should remain clear and free of any visible solids; crystallization may occur if subjected to lower temperatures.

Handling and Disposal

Contrix is provided in a single-dose container. Therefore, any unused portion must be discarded immediately after the procedure to prevent contamination. The product is NOT FOR INTRATHECAL USE (injection into the spine). Expired or unused product must be disposed of in accordance with local environmental and regulatory requirements for chemical waste, and must not be discharged to sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Contrix found in:

A-Z Index: